Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tecemotide

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

- PMLiVE

Novo drops late-stage haemophilia candidate vatreptacog alfa

Patients developed anti-drug antibodies during phase III clinical trial

- PMLiVE

Bayer gets US green light for colorectal cancer drug Stivarga

Follows FDA approval for Sanofi and Regeneron's Zaltrap in same indication

- PMLiVE

Developing drugs to conquer cancer

Future treatments for suppression of antitumour activity, metastatic melanoma and NSCLC were showcased at ASCO 2012 with some exciting results

- PMLiVE

This month in 1901: Birth of Charles Brenton Huggins

This month in pharma: September 1901, the birth of the man who linked hormones with cancer

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

China flag thumb

China slashes drug prices as healthcare reforms announced

Raft of measures to cut healthcare costs include 17 per cent price reduction for cancer drugs

- PMLiVE

Targacept to cut more jobs after ADHD trial failure

TC-5619 disappoints in phase II trial after missing primary endpoint

- PMLiVE

Sanofi taps Oncodesign for kinase inhibitor platform

French firms form €130m alliance

- PMLiVE

Finalists decided in UK cancer awards

QiC Excellence in Oncology aims to recognise good practice in cancer care throughout UK

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links